San Antonio Breast Cancer Symposium

Leigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.

Nicholas Turner, PhD, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Postneoadjuvant bisphosphonate therapy in women with residual invasive disease following chemotherapy for primary breast cancer does not improve clinical outcomes, according to an interim analysis of a large phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.

Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Andrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.

Julie R. Gralow, MD, from the Seattle Cancer Care Alliance, discusses the SWOG S0500 trial, which evaluated different therapies for patients with metastatic breast cancer who had elevated circulating tumor cell levels.

The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.

Antiangiogenic therapy with ramucirumab, an investigational agent that binds to VEGFR-2, added to first-line docetaxel failed to delay the progression of HER2-negative metastatic breast cancer.

Switching chemotherapy based on level of elevated circulating tumor cells after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.

The addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response rates in patients with triple-negative breast cancer.

The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.

Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

Matthew J. Ellis, MD, PhD, from the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.

Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 as a treatment for patients with breast cancer.

In women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS),

PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR). The lowest pCR was observed in HER2+/hormone receptor-positive (HR+), PIK3CA-mutated tumors.

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

A prescribed exercise program reduces joint pain in breast cancer survivors taking AIs, with pain reductions observed at all levels of exercise.

Anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.

Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.

The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial.

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.